Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Shandong Xinhua Pharmaceutical Company Limited is a leading Chinese pharmaceutical manufacturer specializing in both generic and specialty drugs, with a strong presence in the domestic market and expanding international operations. The company benefits from its extensive product portfolio, including active pharmaceutical ingredients (APIs) and finished dosage forms, which positions it competitively in the growing healthcare sector.
Shandong Xinhua generates revenue primarily through the production and sale of generic and specialty pharmaceuticals, leveraging its established manufacturing capabilities and regulatory approvals. The company benefits from cost advantages due to its scale and local sourcing of raw materials, allowing for competitive pricing in both domestic and international markets.
Regulatory approvals for new drug formulations
Changes in domestic healthcare policy affecting drug pricing
International market expansion and export growth
Raw material price fluctuations impacting margins
Regulatory changes in drug approval processes that could delay product launches
Technological advancements leading to new treatment modalities that could render existing products obsolete
Intensifying competition from both domestic and international generic manufacturers
Potential price erosion due to aggressive pricing strategies from competitors
Moderate liquidity risk, although current ratio is healthy at 1.76
Potential foreign exchange risk due to increasing international sales
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but demand can be affected by consumer spending and healthcare budgets.
Rising interest rates can increase financing costs for capital expenditures and R&D investments, potentially impacting profitability and valuation multiples.
minimal - The company has a low debt-to-equity ratio of 0.36, indicating limited reliance on external financing.
value - The stock is currently trading at a low price-to-sales ratio of 0.7x, appealing to value investors looking for recovery potential.
moderate - Historical volatility is in line with industry averages, with a beta around 1.2.
